Clearmind Competitors
| CMND Stock | USD 2.17 0.02 0.91% |
Clearmind Medicine vs Xenetic Biosciences Correlation
Very poor diversification
The correlation between Clearmind Medicine Common and XBIO is 0.86 (i.e., Very poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Clearmind Medicine Common and XBIO in the same portfolio, assuming nothing else is changed.
Moving together with Clearmind Stock
| 0.8 | EVGN | Evogene | PairCorr |
| 0.69 | IMNN | Imunon Inc | PairCorr |
| 0.65 | IPHA | Innate Pharma | PairCorr |
| 0.79 | LYRA | Lyra Therapeutics | PairCorr |
| 0.78 | MBIO | Mustang Bio | PairCorr |
Moving against Clearmind Stock
| 0.78 | ARWR | Arrowhead Pharmaceuticals | PairCorr |
| 0.65 | MRKR | Marker Therapeutics | PairCorr |
| 0.47 | CING | Cingulate | PairCorr |
| 0.45 | MOLN | Molecular Partners | PairCorr |
| 0.34 | CRDF | Cardiff Oncology Buyout Trend | PairCorr |
Clearmind Medicine Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Clearmind Medicine and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Clearmind and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Clearmind Medicine Common does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Clearmind Stock performing well and Clearmind Medicine Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Clearmind Medicine's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| TTNP | 3.46 | 0.32 | 0.04 | (0.16) | 5.38 | 9.38 | 30.41 | |||
| SILO | 3.46 | (0.71) | 0.00 | (0.29) | 0.00 | 8.33 | 24.79 | |||
| KZIA | 7.93 | 0.16 | 0.03 | 0.07 | 10.16 | 14.69 | 78.79 | |||
| CANF | 4.90 | (0.99) | 0.00 | 0.58 | 0.00 | 10.40 | 38.42 | |||
| CNSP | 3.54 | (0.53) | 0.00 | (0.57) | 0.00 | 7.22 | 26.44 | |||
| SNGX | 3.56 | (0.29) | 0.00 | (0.14) | 0.00 | 7.03 | 30.10 | |||
| GRI | 7.57 | (3.38) | 0.00 | 2.05 | 0.00 | 11.88 | 77.14 | |||
| CLDI | 2.74 | (0.64) | 0.00 | (0.45) | 0.00 | 4.80 | 24.52 | |||
| JAGX | 7.07 | (1.04) | 0.00 | (0.23) | 0.00 | 9.71 | 125.57 | |||
| XBIO | 3.34 | (0.77) | 0.00 | (0.46) | 0.00 | 4.76 | 20.89 |
Cross Equities Net Income Analysis
Compare Clearmind Medicine Common and related stocks such as Titan Pharmaceuticals, Silo Pharma, and Kazia Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KZIA | (17.1 M) | 1.3 M | (1 M) | (7.5 M) | (7.1 M) | (12.1 M) | (10.7 M) | (6 M) | (10.3 M) | (12.5 M) | (8.4 M) | (25 M) | (20.5 M) | (26.8 M) | (20.7 M) | (23.8 M) | (25 M) |
| CANF | (3.7 M) | (6.7 M) | (5.6 M) | (8.3 M) | (6.1 M) | (4.8 M) | (6.9 M) | (5 M) | (6.6 M) | (12.6 M) | (14.4 M) | (12.6 M) | (10.2 M) | (7.6 M) | (7.9 M) | (7.1 M) | (7.4 M) |
| CNSP | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (526.5 K) | (7.4 M) | (3.9 M) | (9.5 M) | (14.5 M) | (15.3 M) | (18.9 M) | (14.9 M) | (13.4 M) | (14 M) |
| SNGX | (1.2 M) | (2.4 M) | (4.2 M) | (10.1 M) | (6.7 M) | (7.8 M) | (3.2 M) | (7.1 M) | (8.9 M) | (9.4 M) | (17.7 M) | (12.6 M) | (13.8 M) | (6.1 M) | (8.3 M) | (7.4 M) | (7.8 M) |
| JAGX | (25.5 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (16.3 M) | (14.7 M) | (22 M) | (32.1 M) | (38.5 M) | (33.8 M) | (52.6 M) | (47.5 M) | (41.3 M) | (38.5 M) | (34.6 M) | (36.4 M) |
| XBIO | (6.3 M) | (6.3 M) | (6.3 M) | (8.6 M) | (14.3 M) | (12.5 M) | (54.2 M) | (3.6 M) | (7.3 M) | (12.8 M) | (10.9 M) | (5.6 M) | (6.6 M) | (4.1 M) | (4 M) | (4.6 M) | (4.8 M) |
Clearmind Medicine Common and related stocks such as Titan Pharmaceuticals, Silo Pharma, and Kazia Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Clearmind Medicine Common financial statement analysis. It represents the amount of money remaining after all of Clearmind Medicine Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Clearmind Medicine Competitive Analysis
The better you understand Clearmind Medicine competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Clearmind Medicine's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Clearmind Medicine's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Clearmind Medicine Competition Performance Charts
Five steps to successful analysis of Clearmind Medicine Competition
Clearmind Medicine's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Clearmind Medicine Common in relation to its competition. Clearmind Medicine's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Clearmind Medicine in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Clearmind Medicine's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Clearmind Medicine Common, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Clearmind Medicine position
In addition to having Clearmind Medicine in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Copper Thematic Idea Now
Copper
Companies involved in production of copper. The Copper theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Copper Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Clearmind Medicine Correlation with its peers. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Will Biotechnology sector continue expanding? Could Clearmind diversify its offerings? Factors like these will boost the valuation of Clearmind Medicine. Projected growth potential of Clearmind fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Clearmind Medicine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Clearmind Medicine Common requires distinguishing between market price and book value, where the latter reflects Clearmind's accounting equity. The concept of intrinsic value—what Clearmind Medicine's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Clearmind Medicine's price substantially above or below its fundamental value.
It's important to distinguish between Clearmind Medicine's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Clearmind Medicine should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Clearmind Medicine's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.